The Effect and Safety of a Novel CGM-Based Titration Algorithm for Basal Insulin in T2DM Participants.

Prior treatment

• Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days of the screening visit
• Current/prior use of CGM within 30 days of the screening visit
• Any planned surgery or procedures where basal insulin would be decreased or held in anticipation

Other illness

• Hypersensitivity to Degludec
• Any disorder, except for conditions associated with T2D, which in the investigator's opinion might jeopardize participant's safety or compliance with the protocol.

Other

• Use of an insulin pump
• Use of a short-acting insulin
• Participation or has participated in another trial within 90 days of the screening visit
• Female who is pregnant or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method
• Known skin reactions to CGM adhesives

• Age 18 years or older at signing of informed consent
• Diagnosis of Type 2 Diabetes minimum 180 days before the day of screening
• Hemoglobin A1c between 7-9% and measured by local lab at screening
• On daily basal insulin for at least 90 days before inclusion into the study
• Stable dose of oral and injectable (other than insulin) antidiabetic medications for 90 days prior inclusion. Acceptable medications include:
  • Metformin
  • Sulfonylureas
  • Meglitinides (glinides)
  • Dipeptidyl peptidase 4 (DPP-4) inhibitors
  • Sodium glucose co-transporter 2 (SGLT2) inhibitors
  • Thiazolidinediones
  • Alpha-glucosidase inhibitors
  • Oral combination products (for the allowed individual oral anti-diabetic drugs)
  • Oral or injectable Glucagon-like peptide-1 (GLP-1) Receptor Agonists (RAs)
  • If on sulfonylureas or glinides, willingness to reduce dose by 50%